MEDICATION TREATMENT OF HOSPITALIZED PATIENTS WITH COVID-19: ANALYSIS IN A PUBLIC HOSPITAL IN TOCANTINS
DOI:
https://doi.org/10.56238/arev7n8-096Keywords:
SARS-CoV-2, Drug Treatment, SymptomsAbstract
Introduction: The Covid-19 pandemic required rapid therapeutic decision-making, often based on limited evidence. In Brazil, public hospitals faced additional challenges in adopting effective protocols. Objective: To evaluate the drug treatment used in hospitalized Covid-19 patients in a public hospital in Tocantins, considering the association between the therapeutic classes administered and clinical outcomes. Method: A quantitative, descriptive, and retrospective study, based on the analysis of 197 medical records of patients with a confirmed diagnosis of Covid-19, hospitalized at the Hospital Geral de Palmas (TO) between April and December 2020. The statistical analysis used Cox Regression and normality tests. Results: Most patients were male (66.5%), with a mean age of 58 years, with a standard deviation of 16. The mean length of hospital stay was 10 days, with a standard deviation of 7. Death occurred in 37.1% of cases. The most used medication classes were antibiotics (98.5%), corticosteroids (85.8%), and anticoagulants (84.8%). Polypharmacy (use of ≥5 classes) was observed in 64% of cases. Conclusion: The widespread use of antibiotics and corticosteroids reflects clinical practices adopted in the early months of the pandemic, with a focus on polypharmacy and its impact on clinical outcomes. Studies like this subsidize the revision of therapeutic protocols and strengthen the rational use of medicines in pandemic contexts.
Downloads
References
BATISTA, D. R. et al. Use of anticoagulants in patients with COVID-19: a living systematic review and meta-analysis. Jornal Brasileiro de Pneumologia, v. 49, n. 3, e20230095, 2023. DOI: https://doi.org/10.36416/1806-3756/e20230095
BIANCO, A. et al. Mucolytic and antioxidant properties of carbocysteine as a strategy in COVID-19 therapy. Life, v. 12, n. 11, 1824, 2022. DOI: https://doi.org/10.3390/life12111824
BRASIL. Ministério da Saúde. Diretrizes Brasileiras para o Tratamento Hospitalar do Paciente com COVID-19. Brasília: Ministério da Saúde, 2022.
DURMUS, E. et al. Polypharmacy and its association with clinical outcomes in hospitalized patients with COVID-19. Journal of Infection and Public Health, v. 14, n. 10, p. 1333–1339, 2021.
FALAVIGNA, M. et al. Diretrizes para o tratamento farmacológico da Covid-19: posicionamento da Associação de Medicina Intensiva Brasileira, da Sociedade Brasileira de Infectologia e da Sociedade Brasileira de Pneumologia e Tisiologia. Revista Brasileira de Terapia Intensiva, v. 34, n. 2, p. 195–216, 2022. DOI: https://doi.org/10.54143/jbmede.v2i1.69
GHASEMI, M. et al. Global prevalence and consequences of polypharmacy in COVID-19: a systematic review and meta-analysis. Frontiers in Pharmacology, v. 13, 937472, 2022.
GIL, A. C. Métodos e técnicas de pesquisa social. 7. ed. São Paulo: Atlas, 2019.
GRANATA, G. et al. Antibiotics use in COVID-19 patients: a systematic literature review. Journal of Clinical Medicine, v. 11, n. 23, 7207, 2022. DOI: https://doi.org/10.3390/jcm11237207
JOSHI, S. et al. Role of favipiravir in the treatment of COVID-19. International Journal of Infectious Diseases, v. 102, p. 501-508, 2021. DOI: https://doi.org/10.1016/j.ijid.2020.10.069
MINAYO, M. C. de S. O desafio do conhecimento: pesquisa qualitativa em saúde. 14. ed. São Paulo: Hucitec, 2014.
MORENO, G. et al. Corticosteroid treatment and mortality in mechanically ventilated COVID-19-associated acute respiratory distress syndrome (ARDS) patients: a multicentre cohort study. Annals of Intensive Care, v. 11, p. 1-15, 2021. DOI: https://doi.org/10.1186/s13613-021-00951-0
MORSALI, A. et al. Corticosteroid-based combination therapies for COVID-19: a systematic review and network meta-analysis. Journal of Clinical Pharmacy and Therapeutics, v. 48, n. 2, p. 288-299, 2023.
PANAHI, Y. et al. Evaluation the efficacy and safety of N-acetylcysteine inhalation spray in controlling the symptoms of patients with COVID-19: An open-label randomized controlled clinical trial. Journal of Medical Virology, v. 95, n. 1, e28393, 2023. DOI: https://doi.org/10.1002/jmv.28393
PASCARELLA, A. et al. COVID-19: a systematic review and meta-analysis of observational studies. Frontiers in Pharmacology, v. 11, p. 1109, 2020.
PATEL, C. et al. Effect of corticosteroid therapy on mortality in COVID-19 patients—A systematic review and meta-analysis. Reviews in Medical Virology, v. 32, n. 5, e2386, 2022. DOI: https://doi.org/10.1002/rmv.2386
POPP, M. et al. Ivermectin for preventing and treating COVID-19. Cochrane Database of Systematic Reviews, n. 7, 2021. RABBI, F. et al. Overprescription of antibiotics for treating hospitalized COVID-19 patients: a systematic review & meta-analysis. Heliyon, v. 9, n. 10, e20563, 2023. DOI: https://doi.org/10.1016/j.heliyon.2023.e20563
RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19—Preliminary Report. New England Journal of Medicine, 2020.
STERNE, J. A. C. et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA, v. 324, n. 13, p. 1330-1341, 2020.
YU, Y. et al. One stone two birds: anti-inflammatory bronchodilators as a potential pharmacological strategy for COVID-19. Frontiers in Pharmacology, v. 14, p. 1185076, 2023. DOI: https://doi.org/10.3389/fphar.2023.1185076
